Daily Respiratory Research Analysis
Three impactful studies advanced respiratory science today: a Nature Communications study revealed a basal-shift transformation as a novel mechanism of EGFR-TKI resistance in lung adenocarcinoma with therapeutic sensitivity to CDK4/6 inhibition; a large prospective cohort linked repeated perinatal antibiotics in very-low-birth-weight preterm infants to impaired lung function and more early childhood asthma; and an EBioMedicine multicenter study optimized nanopore-based metagenomic sequencing of
Summary
Three impactful studies advanced respiratory science today: a Nature Communications study revealed a basal-shift transformation as a novel mechanism of EGFR-TKI resistance in lung adenocarcinoma with therapeutic sensitivity to CDK4/6 inhibition; a large prospective cohort linked repeated perinatal antibiotics in very-low-birth-weight preterm infants to impaired lung function and more early childhood asthma; and an EBioMedicine multicenter study optimized nanopore-based metagenomic sequencing of BALF, markedly improving pathogen detection in pneumonia.
Research Themes
- Mechanisms of therapy resistance in lung cancer
- Antibiotic stewardship and long-term respiratory outcomes in preterm infants
- Next-generation sequencing diagnostics for pneumonia
Selected Articles
1. Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.
Using a large patient-derived organoid biobank and single-cell profiling, the authors identify a basal-shift phenotype—driven by NKX2-1 loss—that confers EGFR-TKI resistance in lung adenocarcinoma and creates a therapeutic vulnerability to CDK4/6 inhibitors, particularly in tumors with CDKN2A/B loss. This mechanistic insight fills a major gap for resistance without canonical mutations.
Impact: Reveals a previously undefined resistance program with direct therapeutic implications, enabling biomarker-driven repurposing of CDK4/6 inhibitors in EGFR-mutant LUAD.
Clinical Implications: For EGFR-mutant LUAD with NKX2-1 loss/basal-shift and CDKN2A/B loss, CDK4/6 inhibition merits clinical investigation as a resistance-overcoming strategy. Pathology and transcriptomic profiling could stratify patients for such trials.
Key Findings
- Defined a basal-shift phenotype in EGFR-TKI–resistant LUAD organoids lacking known resistance mutations.
- NKX2-1 knockout induced basal-shift transformation and EGFR-targeted therapy resistance.
- Basal-shift LUADs frequently exhibited CDKN2A/B loss and were sensitive to CDK4/6 inhibitors.
Methodological Strengths
- Comprehensive translational platform using a patient-derived organoid biobank with single-cell profiling.
- Causal validation via prospective gene engineering (NKX2-1 knockout) and pharmacologic testing.
Limitations
- Predominantly preclinical data; clinical validation in patient cohorts is needed.
- Biomarker thresholds and prevalence of basal-shift across unselected clinical populations remain to be established.
Future Directions: Prospective biomarker-driven trials testing CDK4/6 inhibitors in EGFR-TKI–resistant basal-shift LUAD; multi-omic profiling to define diagnostic criteria and prevalence.
Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective for EGFR-mutant lung adenocarcinoma (LUAD), resistance inevitably develops through diverse mechanisms, including secondary genetic mutations, amplifications and as-yet undefined processes. To comprehensively unravel the mechanisms of EGFR-TKI resistance, we establish a biobank of patient-derived EGFR-mutant lung cancer organoids, encompassing cases previously treated with EGFR-TKIs. Through comprehensive molecular profiling including single-cell analysis, here we identify a subgroup of EGFR-TKI-resistant LUAD organoids that lacks known resistance-related genetic lesions and instead exhibits a basal-shift phenotype characterized by the hybrid expression of LUAD- and squamous cell carcinoma-related genes. Prospective gene engineering demonstrates that NKX2-1 knockout induces the basal-shift transformation along with EGFR-target therapy resistance. Basal-shift LUADs frequently harbor CDKN2A/B loss and are sensitive to CDK4/6 inhibitors. Our EGFR-mutant lung cancer organoid library not only offers a valuable resource for lung cancer research but also provides insights into molecular underpinnings of EGFR-TKI resistance, facilitating the development of therapeutic strategies.
2. Optimisation and clinical validation of a metagenomic third-generation sequencing approach for aetiological diagnosis in bronchoalveolar lavage fluid of patients with pneumonia.
A standardized nanopore-based mTGS pipeline for BALF increased diagnostic sensitivity by ~45% over conventional testing and matched mNGS performance, with organism-specific strengths (e.g., higher sensitivity for M. tuberculosis, C. psittaci, S. pneumoniae). The protocol choices (no host depletion; 800 MB depth) are actionable for clinical labs.
Impact: Provides a validated, practical diagnostic workflow that can broaden access to rapid etiological diagnosis of pneumonia with organism-specific advantages.
Clinical Implications: Clinical laboratories can adopt an optimized nanopore mTGS protocol for BALF to improve pathogen detection, particularly for M. tuberculosis and atypical pathogens, to guide targeted therapy and antimicrobial stewardship.
Key Findings
- Optimized parameters (no host DNA depletion; 800 MB depth) improved sensitivity tenfold in reference samples and by 32.5% vs pre-optimized mTGS in the clinical cohort.
- mTGS achieved 84.7% sensitivity versus 39.4% for conventional microbiology and comparable to mNGS (79.9%).
- Organism-specific performance: mTGS more sensitive for M. tuberculosis, Chlamydia psittaci, and Streptococcus pneumoniae; mNGS favored for NTM, Pneumocystis jirovecii, and Aspergillus spp.
Methodological Strengths
- Prospective multicenter cohort with head-to-head comparison against CMTs, pre-optimized mTGS, and mNGS.
- Protocol optimization grounded in both reference materials and clinical BALF specimens with organism-level benchmarking.
Limitations
- No randomized outcome study linking mTGS use to clinical endpoints (e.g., time-to-appropriate therapy, mortality).
- Performance trade-offs versus mNGS for certain fungi and NTM; generalizability beyond participating centers needs confirmation.
Future Directions: Pragmatic trials to assess impact on time-to-effective therapy, antimicrobial stewardship, and outcomes; cost-effectiveness analyses; harmonization of reporting thresholds and QA across centers.
BACKGROUND: Metagenomic Third Generation Sequencing (mTGS), based on nanopore technology, has emerged as a promising tool for the rapid diagnosis of pneumonia pathogens. However, this technology currently lacks standardised technical protocols, quality control measures, and comprehensive performance evaluations for the simultaneous detection of bacteria, fungi, and viruses in clinical settings. METHODS: We optimised the mTGS workflow by refining key parameters (cell wall lysis, fragment size selection, host DNA depletion, and sequencing depth) using reference samples and bronchoalveolar lavage fluid (BALF) from eight patients with pneumonia. These optimisations formed the basis for a standardised mTGS protocol. To assess the clinical diagnostic value of the optimised mTGS, a multicentre prospective cohort study involving 313 pneumonia-suspected patients was conducted. Each BALF sample was tested using conventional microbiological testing (CMTs), metagenomic next-generation sequencing (mNGS), pre-optimised mTGS, and optimised mTGS. FINDINGS: The optimised mTGS protocol, based on the refined cell wall lysis, fragment size selection, no host DNA depletion, and 800 MB sequencing depth, achieved a tenfold increase in sensitivity compared with pre-optimised mTGS for detecting the species of Bacillus subtilis, Mycobacterium tuberculosis, Mycobacterium avium, Cryptococcus neoformans, and Human papillomavirus in reference samples. In the prospective cohort, 274 patients with a confirmed diagnosis of pneumonia were identified, yielding 376 distinct microbes. The mTGS identified more microbes than CMTs (314 vs. 115), with a 45.30% increase in sensitivity (84.70% vs. 39.40%, P < 0.01, Chi-square test/Fisher's exact test). Compared with pre-optimised mTGS, the sensitivity of optimised mTGS increased by 32.51% (84.70% vs. 52.19%, P < 0.01, Chi-square test/Fisher's exact test). mTGS showed comparable performance to mNGS (84.70% vs. 79.90%, P = 0.14,Chi-square test/Fisher's exact test), both significantly outperforming CMTs. mNGS was more sensitive for detecting Non-tuberculous mycobacteria, Pneumocystis jirovecii, and Aspergillus spp., while mTGS demonstrated higher sensitivity for M. tuberculosis, Chlamydia psittaci, and Streptococcus pneumoniae. The overall diagnostic agreement between mTGS and clinical diagnosis was 81.80%. INTERPRETATION: We optimised and validated a standardised mTGS protocol that significantly improved the ability to detect pathogens in the BALF of patients with pneumonia. Optimised mTGS demonstrated comparable performance to mNGS, making it a promising tool for the aetiological diagnosis of pneumonia.
3. Perinatal Antibiotic Exposure and Respiratory Outcomes in Children Born Preterm.
In >3,000 cesarean-born VLBW preterm children, higher perinatal antibiotic exposure (ARS) was dose-dependently associated with lower FEV1/FVC z-scores at 5–7 years and a nearly twofold increase in early childhood asthma. Findings support minimizing non-essential antenatal and postnatal antibiotic courses and targeted follow-up.
Impact: Provides large-scale, prospective evidence linking repeated perinatal antibiotic exposure to later obstructive respiratory outcomes in preterm children, informing stewardship and long-term respiratory care.
Clinical Implications: Avoid non-essential maternal and neonatal antibiotic courses in VLBW preterm infants where safe alternatives exist; implement early respiratory follow-up for high-ARS infants to mitigate later morbidity.
Key Findings
- Higher antibiotic risk score was associated with lower FEV1 z-score (ARS II vs I β −0.31; ARS III vs II β −0.27).
- Greater exposure (ARS III vs II) was linked to reduced FVC z-score (β −0.23) and higher odds of early childhood asthma (OR 1.91).
- Population-based, multicenter cohort across 58 centers with standardized school-age follow-up (5–7 years).
Methodological Strengths
- Large, population-based multicenter cohort with standardized, long-term spirometric outcomes.
- Dose–response analysis using a predefined antibiotic risk score and multivariable modeling.
Limitations
- Observational design with potential residual confounding; post hoc restriction to cesarean-born infants.
- Generalizability beyond the GNN and healthcare context may be limited.
Future Directions: Mechanistic studies on microbiome/immune development pathways; interventional stewardship trials to reduce unnecessary perinatal antibiotic exposure and assess long-term pulmonary outcomes.
IMPORTANCE: Animal models suggest a link between early antibiotic exposure and obstructive airway disease, but corresponding data for premature infants are lacking. OBJECTIVE: To investigate whether repeated perinatal antibiotic exposure in preterm neonates with very low birth weight (VLBW) is associated with obstructive airway disease at early school age. DESIGN, SETTING, AND PARTICIPANTS: In this population-based, multicenter cohort study, VLBW preterm neonates (22 weeks 0 days' to 36 weeks 6 days' gestation with birth weight <1500 g) were enrolled in 58 German Neonatal Network (GNN) centers from January 2009 to March 2017 and received a standardized follow-up at 5 to 7 years of age. To assess the sequential outcomes of antibiotic exposures, the post hoc analysis was restricted to participants born by cesarean delivery. Data were analyzed from May 2024 to February 2025. EXPOSURE: Perinatal antibiotic exposure, defined by an antibiotic risk score (ARS). MAIN OUTCOME AND MEASURES: The primary end point was the forced expiratory volume in 1 second (FEV1) z score at 5 to 7 years of age. The low-risk (ARS I) group was exclusively exposed to surgical antimicrobial prophylaxis (SAP) given to the mother before cesarean delivery. The intermediate-risk (ARS II) group was exposed to maternal SAP and postnatal antibiotic treatment of the neonate, while the high-risk (ARS III) group was additionally exposed to antenatal maternal treatment. Secondary outcomes included forced vital capacity (FVC) z score and childhood asthma episodes. Univariate and linear regression models were used to analyze outcome measures. RESULTS: Of 3820 VLBW preterm-born children with follow-up at age 5 to 7 years (median gestational age, 28.4 weeks [IQR, 26.6-30.3 weeks]; 1948 [51.0%] male; 1382 [36.2%] from a multiple birth), 3109 (81.4%) were born by cesarean delivery. Of these children, 292 (9.4%) were classified into ARS I, 1329 (42.7%) into ARS II, and 1488 (47.9%) into ARS III. Higher ARS levels were associated with lower FEV1 z scores at early school age (ARS II vs I: β, -0.31 [95% CI, -0.59 to -0.02]; P = .03; ARS III vs II: β, -0.27 [95% CI, -0.46 to -0.08]; P = .006). In the secondary analysis, a higher exposure level (ARS III vs II) was associated with impaired FVC z scores (β, -0.23; 95% CI, -0.43 to -0.03; P = .02) and an increased risk of early childhood asthma episodes (odds ratio, 1.91; 95% CI, 1.32-2.76; P = .001). CONCLUSIONS AND RELEVANCE: In this GNN cohort study, multiple episodes of perinatal antibiotic exposure were associated with impaired lung function in preterm-born children at early school age. Early identification of high-risk neonates may enable targeted strategies to support respiratory health and optimize long-term outcomes.